Evidence map›Paper›PMID 34748737›Full record

ReviewAnnales pharmaceutiques francaises2022

[Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].

A Dubois, A Féral, J-B Pain, J Michot, D Fansi Ndengoue, A Benomar, E Clou, I Debrix

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annales pharmaceutiques francaises, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

A DuboisService pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France. Electronic address: antonin.dubois@aphp.fr.
A FéralService pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
J-B PainService pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
J MichotCentre régional de pharmacovigilance, sites Pitié Salpétrière et Saint-Antoine, Sorbonne université, AP-HP, 75012 Paris, France.
D Fansi NdengoueCentre régional de pharmacovigilance, sites Pitié Salpétrière et Saint-Antoine, Sorbonne université, AP-HP, 75012 Paris, France.
A BenomarService pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
E ClouService pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
I DebrixService pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
Hôpital Tenon · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of the study is to provide an overview of Drug-drug Interactions (DDIs) and adverse effects caused by drugs used in SARS-CoV-2 infection during the first epidemic wave.

methodsWe retrospectively analyzed patients treated by drugs used in SARS-CoV-2 infection (Azithromycin, Hydroxychloroquine and/or Lopinavir/ritonavir) between 15th March 2020 to 17th April 2020. A review of adverse events and DDI-risky drug association on medical record was conducted for each patient. Each adverse events was analyzed by the Centre régional de pharmacovigilance (CRPV) to assess causality of drugs used in SARS-CoV-2 infection.

resultsA total of 312 precriptions were analyzed during the period, of which 110 prescriptions had 157 drug association at risk of DDIs; 26 adverse events were reported. Causality assessment by CRPV concluded that 10 (35,7 %) adverse effects were possibly related to SARS-CoV-2 drugs with only 2 (7,1 %) related to DDIs.

conclusionsDespite risk of adverse drug reactions and DDIs related to drugs used in SARS-CoV-2 infection, few iatrogenics diseases were found.

Indexed as

COVID-19 Drug TreatmentAntiviral AgentsDrug InteractionsHumansHydroxychloroquineRetrospective StudiesRitonavirSARS-CoV-2Antiviral AgentsHydroxychloroquineRitonavirAdverse drug reactionCOVID-19Drug-drug interactionEffets secondaires et réactions indésirables d’origine médicamenteuseIncompatibilité entre médicamentsSARS-CoV-2

Identifiers

PMID34748737
PMCPMC8570435
OpenAlexW3213692673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.